Sunshine Lake Pharma (HKG:6887) has launched an artificial intelligence-powered research and development platform focused on PROTAC (Protein Degradation-Targeting Chimeras) drug discovery, according to a Wednesday Hong Kong bourse filing.
Shares of the firm were down nearly 1% in Thursday morning trade.
The company said the platform integrates data analysis, computational modelling, and laboratory validation to support the design of PROTAC compounds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.